SAN DIEGO, March 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at 2:05 p.m. ET (11:05 a.m. PT) in Miami.
A live audio webcast of the presentation will be accessible on the "Investors" page of Mirati's corporate website at www.mirati.com. A replay of the presentation will be available at the same location for 60 days following the conference.
About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.
Logo - http://photos.prnewswire.com/prnh/20160307/341355LOGO
SOURCE Mirati Therapeutics, Inc.